Most Read Articles
Pank Jit Sin, 13 May 2020
A trial vaccine for the prevention of COVID-19 is underway with the first US participants being dosed in the Phase 1/2 clinical trial. Known as the BNT162 vaccine programme, the trials are a collaboration between Pfizer Inc. and BioNTech SE, and is part of a global development programme with Germany and the US taking the lead in having the first cohorts to be vaccinated. Germany started the study 1 week earlier. 
Jairia Dela Cruz, 18 Dec 2020
Rinsing with mouthwash that contains povidone-iodine (PI) or cetylpyridinium chloride (CPC) helps reduce SARS-CoV-2 levels in the saliva of COVID-19 patients, with the effect persisting for up to 6 hours, as shown in a study from Singapore.

ACEI/ARBs fight off confusion among hypertensive COVID-19 patients

21 Nov 2020

The use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) seem to protect against confusion in patients of the novel coronavirus disease (COVID-19) with hypertension, a recent Japan study has found.

The study included 151 COVID-19 patients, of whom 39 were hypertensive (mean age, 71±12 years; 69.2 percent male). The primary outcome was a composite of in-hospital death, extracorporeal membrane oxygenation, invasive and noninvasive mechanical ventilation, and admission into the intensive care unit (ICU). Outcomes were compared to 112 patients without hypertension (mean age, 56±20 years; 56.3 percent male).

Of the 39 hypertensive participants, 22 were on ACEI/ARB medication. Fourteen in-hospital deaths were recorded, yielding an overall rate of 9.3 percent. Fourteen and 58 patients required mechanical ventilation or oxygen therapy, respectively.

Multivariate logistic regression analyses showed that age was the strongest and most consistent risk factor for all outcomes assessed. Participants ≥65 years of age, for example, saw a sixfold spike in the likelihood of the primary composite outcome occurring (odds ratio [OR], 6.63, 95 percent confidence interval [CI], 2.28–22.78; p<0.001).

Similarly, these patients were more than four times as likely to develop the secondary composite endpoint (OR, 4.53, 95 percent CI, 1.72–13.20; p=0.002), which included low admission systolic blood pressure and new-onset or worsening mental confusion, among others.

Notably, while ACEI/ARB use had no significant benefit with regard to the primary and secondary composite outcomes, it exerted a significant protective effect against new-onset confusion, reducing the odds by nearly 90 percent (OR, 0.13, 95 percent CI, 0.01–0.93; p=0.041).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pank Jit Sin, 13 May 2020
A trial vaccine for the prevention of COVID-19 is underway with the first US participants being dosed in the Phase 1/2 clinical trial. Known as the BNT162 vaccine programme, the trials are a collaboration between Pfizer Inc. and BioNTech SE, and is part of a global development programme with Germany and the US taking the lead in having the first cohorts to be vaccinated. Germany started the study 1 week earlier. 
Jairia Dela Cruz, 18 Dec 2020
Rinsing with mouthwash that contains povidone-iodine (PI) or cetylpyridinium chloride (CPC) helps reduce SARS-CoV-2 levels in the saliva of COVID-19 patients, with the effect persisting for up to 6 hours, as shown in a study from Singapore.